Filing Details
- Accession Number:
- 0001415889-24-008107
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-03-15 16:15:21
- Reporting Period:
- 2024-03-13
- Accepted Time:
- 2024-03-15 16:15:21
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1516551 | Skye Bioscience Inc. | SKYE | () | 4 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1219014 | M Scott Rocklage | 501 2Nd Street, Suite 350 San Francisco CA 94107 | No | No | Yes | No | |
1240357 | D John Diekman | 501 2Nd Street, Suite 350 San Francisco CA 94107 | No | No | Yes | No | |
1386509 | 5Am Ventures Ii Lp | 501 2Nd Street, Suite 350 San Francisco CA 94107 | No | No | Yes | No | |
1390376 | 5Am Co-Investors Ii Lp | 501 2Nd Street, Suite 350 San Francisco CA 94107 | No | No | Yes | No | |
1555952 | 5Am Partners Ii, Llc | 501 2Nd Street, Suite 350 San Francisco CA 94107 | No | No | Yes | No | |
1664281 | Kush Parmar | 501 2Nd Street, Suite 350 San Francisco CA 94107 | No | No | Yes | No | |
1844435 | 5Am Ventures Vii, L.p. | 501 2Nd Street, Suite 350 San Francisco CA 94107 | No | No | Yes | No | |
1873545 | 5Am Partners Vii, Llc | 501 2Nd Street, Suite 350 San Francisco CA 94107 | No | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2024-03-13 | 450,000 | $10.00 | 8,393,520 | No | 4 | P | Indirect | By 5AM Ventures VII, L.P. |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | P | Indirect | By 5AM Ventures VII, L.P. |
Reported Non-Derivative Holdings
Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
---|---|---|---|
Common Stock | 1,718,189 | Indirect | By 5AM Ventures II, L.P. |
Common Stock | 67,796 | Indirect | By 5AM Co-Investors II, L.P. |
Footnotes
- The securities are directly held by 5AM Ventures VII, L.P. ("Ventures VII"). 5AM Partners VII, LLC ("Partners VII") is the sole general partner of Ventures VII. Dr. Kush Parmar and Andrew J. Schwab are the managing members of Partners VII and may be deemed to have shared voting and investment power over the securities beneficially owned by Ventures VII. Each of Partners VII and Dr. Parmar disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports.
- The securities are directly held by 5AM Ventures II, L.P. ("Ventures II"). 5AM Partners II, LLC ("Partners II") is the sole general partner of Ventures II. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are the managing members of Partners II and may be deemed to have shared voting and investment power over the securities beneficially owned by Ventures II. Each of Partners II, Dr. Diekman and Dr. Rocklage disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports.
- The securities are directly held by 5AM Co-Investors II, L.P. ("Co-Investors II"). Partners II is the sole general partner of Co-Investors II. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are the managing members of Partners II and may be deemed to have shared voting and investment power over the securities beneficially owned by Co-Investors II. Each of Partners II, Dr. Diekman and Dr. Rocklage disclaims beneficial ownership of such shares except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports.